Epirubicin: all 157 studies that test it

Page 1 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic CarcinomaNot yet recruitingNCT07616141Phase 2
• Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective StudyRecruitingNCT07320508Phase 2
• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast CancerRecruitingNCT06291064Phase 2
• Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast CancerRecruitingNCT06227117Phase 2
• Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived OrganoidsNot yet recruitingNCT06227065Phase 2
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingNCT06121570Phase 1
• A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerRecruitingNCT05862064Phase 3
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
• A Study for the Adjuvant Treatment of Breast CancerRecruitingNCT05420467Phase 4
• A Study for the Neoadjuvant Treatment of Breast CancerRecruitingNCT05420454Phase 4
• Epirubicin for the Treatment of Sepsis & Septic ShockRecruitingNCT05033808Phase 2
• Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer PatientsRecruitingNCT04836156Phase 1/2
• MicroRNA Profiles in Triple Negative Breast CancerRecruitingNCT04771871Phase 2
• A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of BreastRecruitingNCT02897700Phase 1
• A Study of Genetic Based Chemotherapy Dosing for Breast Cancer PatientsRecruitingNCT01740271Phase 2
• Phase II Trial for Large ER-Negative Breast CancersCompletedNCT01869192Phase 2Results posted
• Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast CancerTerminatedNCT01220128Phase 2Results posted
• Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ AdenocarcinomaCompletedNCT00737438Phase 2Results posted
• Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal AdenocarcinomaTerminatedNCT00667420Phase 1/2Results posted
• Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or StomachCompletedNCT00601705Phase 2Results posted
• Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast CancerCompletedNCT00464646Phase 2Results posted
• Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer PatientsCompletedNCT00432172Phase 2Results posted
• Docetaxel and Epirubicin in Advanced Gastric CancerCompletedNCT00375999Phase 2Results posted
• Phase I Combination w/ EpirubicinCompletedNCT00322374Phase 1Results posted
• Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast CancerCompletedNCT00193206Phase 2Results posted
• Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast CancerCompletedNCT00193050Phase 2Results posted
• Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast CancerTerminatedNCT00176488Phase 2Results posted
• Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast CancerCompletedNCT00087178Phase 3Results posted
• Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal CancerCompletedNCT00052910Phase 3Results posted
• Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast CancerCompletedNCT00014222Phase 3Results posted
• To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast CancerStatus unknownNCT05491694Phase 2
• Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled TrialStatus unknownNCT05146635Not applicable
• Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived OrganoidsActive, not recruitingNCT05024734Phase 2
• Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsCompletedNCT04659551Phase 2
• VR-CAP in the First-line Treatment for Patients With Marginal Zone LymphomaCompletedNCT04433156Phase 2
• NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBCActive, not recruitingNCT04335669Phase 3
• Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast CancerActive, not recruitingNCT04290793Phase 2/3
• Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast CancerCompletedNCT04224922Phase 2
• SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast CancerStatus unknownNCT04213898Phase 1/2
• Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)CompletedNCT04127019Phase 3
• Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's LymphomaActive, not recruitingNCT04067037Phase 2
• Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast CancerCompletedNCT03888677Phase 3
• SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung CancerStatus unknownNCT03755115Phase 2
• The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast CancerStatus unknownNCT03647280Not applicable
• Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast CancerStatus unknownNCT03373708Phase 2/3
• Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant ChemotherapyStatus unknownNCT03349177Phase 2/3
• Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBCCompletedNCT03289819Phase 2
• Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast CancerCompletedNCT02980965Phase 3
• Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric CancerStatus unknownNCT02949258Phase 2
• Denosumab as an add-on Neoadjuvant Treatment (GeparX)CompletedNCT02682693Phase 2
• Efficacy Study of TACE to Treat Hepatocellular Carcinoma After OperationStatus unknownNCT02631499Phase 4
• Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 VariationsCompletedNCT02628613Phase 2
• Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast CancerCompletedNCT02549677Phase 4
• Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast CancerCompletedNCT02365805Phase 2
• A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNATerminatedNCT02363400Phase 3
• Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer PatientsActive, not recruitingNCT02338518Phase 3
• Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- TumorsCompletedNCT02307227Phase 2
• Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder CancerCompletedNCT02214602Phase 4
• Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric CancerTerminatedNCT02076594Phase 3
• Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast CancerTerminatedNCT01985841Phase 2
• A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast CancerStatus unknownNCT01907529Phase 2/3
• Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric CancerTerminatedNCT01830270Phase 2
• ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerCompletedNCT01779206Phase 2/3
• NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)CompletedNCT01726452Phase 3
• A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal CancerCompletedNCT01710592Phase 2
• "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"Status unknownNCT01641406Phase 2
• Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast CancerCompletedNCT01624441Phase 1
• Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast CancerStatus unknownNCT01479036Phase 3
• Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast CancerStatus unknownNCT01428414Phase 2
• The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBCStatus unknownNCT01378533Phase 3
• Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric AdenocarcinomaTerminatedNCT01351038Phase 2
• Early Cardiac Toxicity of Adjuvant CT in Elderly BC.TerminatedNCT01301040Phase 2
• ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal JunctionCompletedNCT01234324Phase 2
• 6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer PatientsStatus unknownNCT01222052Phase 3
• Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic CancerCompletedNCT01150630Phase 2
• R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCLCompletedNCT01148446Phase 3
• Regimens Comparison for Breast Cancers of Positive Lymph NodesStatus unknownNCT01134523Phase 3
• Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)Status unknownNCT01031030Phase 3
• A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years OldCompletedNCT01026116Phase 3
• Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic CancerCompletedNCT00966706Phase 2
• Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By SurgeryCompletedNCT00963729Phase 3
• A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer EarlyStatus unknownNCT00957125Phase 2
• Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid TumorsCompletedNCT00878904Phase 1
• Trial of Transcatheter Arterial Chemoembolization for Hepatocellular CarcinomaStatus unknownNCT00843934Phase 2/3
• REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG CancerTerminatedNCT00824785Phase 3
• Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue SarcomaCompletedNCT00822848Phase 1
• A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver ResectionCompletedNCT00820053Phase 2
• Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer PatientsActive, not recruitingNCT00798070Phase 3
• A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast CancerCompletedNCT00773695Phase 2
• Sulindac and Epirubicin in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00755976Phase 2
• Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30CompletedNCT00753207Phase 1
• Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)CompletedNCT00743964Phase 2
• A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid TumorsCompletedNCT00722293Phase 1
• Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast CancerCompletedNCT00705315Phase 1/2
• Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph NodesCompletedNCT00668616Phase 3
• Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung CancerCompletedNCT00658580Phase 3
• Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast CancerCompletedNCT00645866Phase 2
• Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: FeasibilityCompletedNCT00617370Not applicable
• Neoadjuvant Endostatin and Chemotherapy for Breast CancerCompletedNCT00604435Phase 2

← Epirubicin overview